Brief Summary
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomycomplete or partial removal of the prostate gland in Men with Newly Diagnosed Prostatea walnut-shaped gland in the male reproductive system that is responsible for producing semen - a bodily fluid that acts as a vessel for sperm transport during ejaculation Cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (ASCERTAIN).
Intervention / Treatment
- Drug: Saruparib (AZD5305)
- Drug: Darolutamide
- Other: No Treatment
Inclusion Criteria:
- male participants >/= 18 years old
- participants deemed suitable for radical prostatectomy
- participants with localisedaffecting only one area of body prostate cancer with unfavourable intermediate/high/very high riskthe possibility that something bad will happen eligible for prostatectomy
- adequate organ and marrow function as per protocol
- capable of giving signed informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment.
- For participants participating in the Optional Genetic Research Only: Provision of signed and dated written Optional Genetic Research Information
- Available FFPE diagnostic tumoura tissue mass that forms from groups of unhealthy cells biopsyremoval of a section of tissue to analyse for cancer cells samples
- Participants must use a condom (with spermicide) from screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening to 6 months after screening and refrain from fathering a child or donating sperm.